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The biocultural evolution of inflammatory bowel diseases
Abstract
Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are described as
abnonnal immune responses to the gastrointestinal microbiota. The etiology of IBD is unknown; however,
it is associated with Western, industrialized societies. A better understanding of the origins and
treatments of IBD can lead to improved health outcomes. This paper seeks to examine IBD from a
cultural, environmental, and evolutionary perspective. The effects of cultural and environmental factors,
such as diagnostic practices, diet, breastfeeding practices, antibiotic use, appendectomy, and
environmental radiation exposure on the risk of developing IBD are discussed. The efficacy of various
treatments for IBD will also be examined. This review suggests that IBD constitutes a maladaptive
inflammatory response to microbial ecosystem changes in the gut brought about by a variety of external
factors, including diet, breastfeeding, appendectomy, antibiotic usage, and environmental radiation
exposure.
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Abstract
Inflammatory bowel diseases (IBO}, such as Crohn's disease and ulcerative
colitis, are described as abnonnal immune responses to the gastrointestinal microbiota.
The etiology of IBO is unknown; however, it is associated with Western, industrialized
societies. A better understanding of the origins and treatments of IBO can lead to
improved health outcomes. This paper seeks to examine IBD from a cultural,
environmental, and evolutionary perspective. The effects of cultural and environmental
factors, such as diagnostic practices, diet, breastfeeding practices, antibiotic use,
appendectomy, and environmental radiation exposure on the risk of developing IBO are
discussed. The efficacy of various treatments for IBO will also be examined. This review
suggests that IBO constitutes a maladaptive inflammatory response to microbial
ecosystem changes in the gut brought about by a variety of external factors, including
diet, breastfeeding, appendectomy, antibiotic usage, and environmental radiation
exposure.
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Introduction
Inflammatory bowel diseases (18D) such as Crohn's disease (CD) and ulcerative
colitis (UC) are often characterized by an "abnormal immune response to the intestinal
micro flora of a genetically susceptible individual" (Ananthakrishnan, 2015). Although
the etiology of IBO has been studied extensively, the root cause of the disease is yet to be
understood. In addition, research on the pathogenesis of IBO is becoming of increasing
importance, as epidemiological studies suggest that 18D is quickly becoming a global
disease (Molodecky et al., 2012). Through understanding how various factors influence
the pathogenesis of IBO, better prevention strategies and treatment plans can be
developed. This will ultimately lead to improved patient health outcomes.
It is currently unknown if the recent increase in IBO incidence and prevalence
rates are due to genetic or environmental factors. Although there is some genetic basis for
IBO, monozygous twin studies have suggested that only a 50-60% concordance rate
exists, meaning that genetics can only be partially responsible for the pathogenesis of
IBD {Halfvarson et al., 2003; Orholm et al., 2000). Furthermore, migrant population
studies suggest that racial and ethnic differences in incidence rates of 18D are due to
cultural and environmental differences rather than actual genetic differences (Loftus,
2004). Thus, environmental and cultural influences must play a significant role in the
pathogenesis of IBO, and further research should be conducted in order to understand the
relationship between these factors and the etiology of the disease. Increased risk of IBO
has also been linked to a dysregulated immune response to the intestinal microbiome
(Kostic et al., 2014), and both bacterial and fungal dysbiosis has been observed in the gut
of IBO patients, suggesting that the bacterial and fungal microbiome may play a role in
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IBD pathogenesis (Sokol et al., 2017). Thus, the relationships between these cultural
factors, intestinal microbiota, and the immune response should be studied.
Despite the copious amounts of research on environmental risk factors for IBD,
few studies have examined these environmental factors from a cross-cultural perspective.
Through analyzing these cultural differences and their biological impact, a clearer
understanding of the etiology of IBD may begin to arise. Of particular interest will be
those changes in cultural practices that are associated with the industrialization of
nations, as industrialization is often linked to an increase in risk of IBD
(Ananthakrishnan, 2015).
The goal of this literature review will be to: l ) examine the effect that diagnostic
practices have on IBD incidence and prevalence rates, 2) analyze the biological impact
that cultural and environmental factors such as diet, breastfeeding practices, antibiotic
use, appendectomy, and environmental radiation exposure have on the intestinal
microbiome and the immune response, and 3 ) evaluate the efficacy of common IBD
treatments. It is hypothesized that IBD is caused by a maladaptive immune response to a
gastrointestinal environment that has experienced rapid changes due to industrialization.
Thus, those treatments that restore the gastrointestinal environment to a "healthy" state
should be most beneficial for patients with IBD.

Evolutionary Medicine and IBD
Current evolutionary theory (termed the "modern synthesis"), pioneered by Mayr
and Dobzhanzky and coined by Huxley, combines genetics and Darwinian evolution
(Kutschera and Niklas, 2004). The Darwinian theory of evolution by natural selection has
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four basic principles: I) in each generation, more organisms are produced than can
survive; 2) organisms exhibit variability of traits; 3) some of this variation is heritable;
and 4) those individuals who are better suited for their environments are more likely to
survive and pass down favorable traits. Scientists have revised Darwin's understanding of
evolution to include Mendelian genetics. The four tenets of this "modem synthesis of
evolution" are 1) changes in DNA create changes in the phenotype (observable
characteristics) on which natural selection acts; 2) the phenotypes best suited for the
environment are more likely to survive and reproduce; 3) those phenotypes that survive
will pass on more genes to the next generation; and 4) a change in gene frequency from
one generation to the next is evolution. Through this evolutionary framework, scientists
are able to better understand biological diversity and human variation (Huss-Ashmore,
2000).
According to Darwinian evolution, the environment is the primary driving force
of natural selection. For humans, the environment has been suggested to contain three
aspects: the physical (climate, energy usage, materials, and geology), the biotic (food,
materials, pathogens, symbionts, and predators), and the social (social, economic, and
political structures, material culture, technology, and population dynamics) (Huss
Ashmore, 2000). In all these environments, humans face two challenges: they must avoid
stressors (conditions that may disturb normal biological processes) and find resources for
survival and reproduction (Huss-Ashmore, 2000).
In order to overcome these challenges, humans employ a combination of genetic,
physiological, developmental, cultural and behavioral responses. In addition, although
cultural and behavioral responses attempt to alleviate environmental stressors, they may
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also be the source of environmental stressors for certain sections of the population. For
example, children living in poverty-stricken urban environments are exposed to higher
lead levels than the rest of the population, which can lead to a number of negative
biological outcomes (Huss-Ashmore, 2000). This was the case in the 2014 Flint water
crisis, which had a disparate impact on low-income and minority children and pregnant
women. Intending to save money, state-appointed emergency management chose to
switch the water source from Detroit's Lake Huron to the Flint River. This change
significantly increased lead exposure in low socioeconomic areas within the city limits,
whereas neighborhoods outside the city were not significantly affected (Hanna-Attisha et
al., 2016). Therefore, the environment both affects and is affected by human
biobehavioral responses. Furthermore, analyzing the context in which these responses are
created is important for understanding their success. Responses that are successful in one
context may not be successful in another, and responses that are successful now may not
be successful in the future (Goodman and Leatherman, 2010).
The theory of evolution can also be applied to biomedical contexts. In the field of
evolutionary medicine, human health and illness are understood through analyzing
human evolutionary history. In particular, evolutionary medicine focuses on how
evolutionary trade-offs (traits that are advantageous, but come at a cost) and different
environments impact human health (Huss-Ashmore, 2000). This perspective is thought to
be especially useful for understanding chronic illnesses, like IBO, because it attempts to
understand the ultimate causes of these diseases. In other words, evolutionary medicine
examines how changing environments and lifestyle differences between modem and
ancient humans contribute to modem human health {Trevathan et al., 2008).
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Environmental factors are thought to play a major role inIBO pathogenesis
(Loftus, 2004). Furthennore, the gut microbiome, which is altered inIBD patients (Kostic
et al., 2014; Swidsinski et al., 2002; Swidsinski et al., 2005), is more affected by
environmental factors than by host genetics. For example, cohabitating but genetically
unrelated spouses have gut microbiomes that more closely resemble each other than
individuals from separate households (Yatsunenko et al., 2012).In addition, dogs ( Canis

lupusfamiliaris) have intestinal microbiomes that are more similar to humans than pigs
or mice. This similarity is most likely due to the fact that humans and dogs live in similar
environments (Coelho et al., 2018). Thus, it is likely that cultural and behavioral
responses to environmental stressors may impact the gut microenvironment. These
changes to the gut microenvironment create a new context in which certain adaptations
may be unsuccessful, ultimately leading to chronic digestive diseases such asIBO.

Diagnostic Practices
Better access to healthcare and advances in diagnostic procedures and medical
technology are thought to be important contributing factors for the increased prevalence
and incidence rates ofIBD (Kaplan, 2015; Lakatos, 2006; Loftus, 2004; Molodecky et
al., 2012). In particular, understanding diagnostic changes may help to explain why
newly-industrialized nations experienced an initial increase in rates of UC, followed by
an increase in rates of CD years later (Kaplan, 2015; Lakatos, 2006; Loftus, 2004).In
newly industrialized nations, UC is diagnosed by sigmoidoscopy (which examines only
the rectum and distal colon), but CD diagnosis is rare and is limited to severe cases, such
as those that require surgery. However, as colonoscopy screening increases (which
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examines the entire large intestine and the distal small intestine), milder cases of CD are
more easily detected. Thus, changes in diagnostic practices are responsible for the initial
rise in UC, followed by a rise in CD (Kaplan, 2015). Therefore, understanding how IBO
is diagnosed worldwide is important for understanding the epidemiology of the disease.
In the United States, it is recommended that a patient presenting symptoms of
IBO have an initial evaluation conducted that includes a colonoscopy with intubation and
examination of the terminal ileum (the most distal portion of the small intestine). This
allows for direct visualization of the colon and terminal ileum and for the performance of
any necessary biopsies. Sigmoidoscopy is not suggested for initial evaluation, but may be
used for monitoring patients with established IBD (Spiceland and Lodhia, 2018).
In non-Western societies, diagnostic challenges may arise from overlapping
symptoms of IBD and infectious diseases such as intestinal tuberculosis, which mimics
IBO and lacks strong diagnostic histopathological criteria. For example, access to
healthcare can vary between urban and rural populations and by location (Baumgart et
al., 2011 ). Therefore, it is likely that as access to healthcare and diagnostic technology
improve, there will be an increase the reporting of IBO to health agencies, which will
impact the incidence rates of IBO.
A study conducted by Pavlovic-Calic and colleagues (2008) found that increasing
rates of CD in Tuzla Canton of Bosnia and Herzegovina was directly correlated to
increased availability of colonoscopy. Between 1995 and 1997, the incidence of CD was
about 0.3 per 100,000. By 2006, the incidence of CD had jumped to nearly 5.0 per
l 00,000. This dramatic increase in incidence was determined to be due to an increase the
availability of endoscopy. As a result of the Bosnian War (1992-1995), health-care

10

infrastructure and access to endoscopy had been crippled, and only 29 endoscopies were
performed in 1995. By 2006, conditions had improved, and gastroenterologists reportedly
performed 850 endoscopies (Pavlovic-Catie et al., 2008). This study serves as evidence
that increased incidence of IBO may be due to increased use of colonoscopy.
Better access to healthcare and improved diagnostic techniques are not the only
factors that can affect incidence rates of IBO. In addition to an increase in colonoscopy
usage, the spread of "Western" lifestyle and diet following the civil war were suggested
as possible compounding factors (Pavlovic-Catie et al., 2008). In industrialized nations,
for unknown reasons, the incidence of pediatric-onset IBO has been on the rise (Kaplan,
2015). Thus, although changes in diagnostic practices are a major reason for increased
rates of IBO, they are not the only reason. Although these changes may lead to better
diagnoses, they do not necessarily help to explain the etiology of IBO. Therefore, an
examination of other factors known to impact gastrointestinal health is required.

Immune Response in IBD
IBO is characterized as an aberrant immune response to the gut microbiota in a
genetically susceptible individual (Ananthakrishnan, 2015). In IBO, the immune response
is regulated by both the innate and the adaptive immune system. The innate immune
system is often the first line of defense against pathogens. ln the gut, the innate immune
system includes the epithelial barrier and phagocytic cells (immune cells that engulfs
pathogens, and includes macrophages, dendritic cells, and neutrophils). Although the
innate immune system has no memory for pathogens (Mayer, 2010), it is what normally
protects the gut against harmful bacteria, since the adaptive immune system can take days
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to respond (Weinstock and Elliott, 2009). The majority of genes that have been
discovered to play a role in IBD pathogenesis disrupt the innate immunity of the gut.
Although a mutation in one of these genes is not essential for disease development, those
with a mutation and IBD have earlier disease onset and more aggressive disease
characteristics (Mayer, 2010).
The adaptive immune system has also been found to be involved in the
progression of IBD. This system is mediated by lymphocytes, T cells, B cells, and
antigen receptors. Of these immune cells, T cells are the most correlated with IBO
pathogenesis. T cells are responsible for producing cytokines (cell-signaling molecules)
that affect other immune cells (Mayer, 2010). Unlike innate immunity, the adaptive
immune system responds to specific pathogens and can have memory of them. From an
evolutionary perspective, it has been hypothesized that the regulation of cytokine
production by certain gut symbionts may have played a role in the evolution of the
human immune system. In particular, helminths (parasitic worms) are believed to aid in
the regulation of cytokine production. Therefore, exposure to helminths throughout
human evolution may have affected the evolution of the immune system, and may
continue to regulate immunological processes today. According to the "hygiene
hypothesis," children raised in hygienic environments are not exposed to certain
pathogens and parasites, like helminths, and thus are more susceptible to immune
disorders, such as IBO (Weinstock and Elliott, 2009).
Due to the fact that it must be able to respond to a variety of pathogens and
changing environments, the immune system is plastic by nature (Mayer, 2010). However,
as the hygiene hypothesis suggests, it is important to remember that the immune system
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has evolved alongside a specific gut environment (Weinstock and Elliott, 2009).
Therefore, as the intestinal microenvironment changes in response to external factors, it is
possible that immune responses that have adapted to certain environments are no longer
successful in these new environmental contexts. It is therefore essential to examine the
ways that external factors impact the intestinal ecosystem.

Cultural and Environmental Factors that Impact IBO Risk
D(et
Epidemiological studies on IBD have often found a correlation between
industrialization and an increased risk of IBD (Molodecky et al., 2012). It has been
suggested that urbanization and increased wealth is associated with diets higher in sugar,
animal fats and proteins, and processed foods (Drewnowski and Popkin, t 997).
Furthermore, most IBD patients believe that diet plays a major role in the development of
the disease. Thus, it seems that cultural differences in diet have a large impact on the
pathogenesis and risk of IBD. Although it has been one of the most extensively studied
risk factors, it is also one of the most difficult to research due to the high variation in
individual diet patterns (Ananthakrishnan, 2015). By studying these dietary factors from
a cross-cultural, evolutionary perspective, trends in intestinal microbiology, diet, and
possible etiologies of IBD begin to emerge.
Numerous studies have suggested that the intestinal microbiome of IBD patients
differs greatly from that of healthy individuals (Kostic et al., 20 I 4; Sunkara et al., 2018;
Swidsinski et al., 2002; Swidsinski et al., 2005}. For example, patients with IBD have
been found to have higher amounts of

Bacteroides and Enterobacteriaceae, including E.
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coli, than healthy controls (Swidsinski et al., 2002). In fact, Bacteroides adhesion to the
intestinal mucosa! layer is considered a main feature of the intestinal microbiome in
patients with IBD when compared to healthy individuals (Swidsinski et al., 2005).
Dysbiosis of the fungal microbiome has also been observed in IBO patients. In particular,
the gut microenvironment of CD patients may favor fungi at the expense of bacteria,
suggesting there are inter-kingdom microbial shifts occurring in the GI tract of IBD
patients (Sokol et al., 2017).
In addition to a link between the gut microbiome and 18D, it has been suggested
that shifts in dietary patterns may also shape the taxonomic structure of the intestinal
microbiome, at least temporarily. When fed a Western diet, African green monkeys

(Ch/orocebus aethiops sabaeus) have intestinal microbiomes with increased microbial
richness and relative abundance of Prevotel/a (Amato et al., 2015b). In humans, however,
a shift to a Western diet high in animal fats and proteins has the opposite effect on
microbial taxa, most likely due to dietary and physiological changes that occurred during
human evolution. One US study on healthy individuals found that agrarian, carbohydrate
rich diets were associated with a gut microbiome with high amounts of bacteria
belonging to the Prevotella taxa. In contrast, diets high in animal fats and proteins were
associated with an intestinal microbiome high in Bacteroides (which are associated with
IBD when present in high levels) (Wu et al., 2011). Given that higher amounts of

Bacteroides are observed in IBD patients (Swidsinski et al., 2002; Swidsinski et al.,
2005), there may be a link in humans between a diet high in animal fats and proteins and
IBD risk.
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It has been suggested that differences in response to changes in diet between
humans and non-human primates may be due to dietary and physiological shifts in human
evolution that have affected the microbiota. Changes in this microbiota may have also led
to more efficient energy production and fat storage. Although this potentially increased
brain size and reduced gut size, it additionally may have made humans more susceptible
to obesity and metabolic disorders in times when food resources are abundant (Amato et
al., 2015b). As obesity has been linked to increased inflammation (Celiberto et a/., 2018),
it is possible that increased susceptibility to obesity may also increase susceptibility to
chronic inflammatory disorders, such asIBO.
Significant differences in the composition of the microbiota of agrarian and
industrial societies have also been observed. A study comparing the intestinal microtlora
of children in Burkina Faso, whereIBO is a rare occurrence, to that of children ofItaly,
whereIBO is relatively common, found that the microflora of the populations differs
significantly. Although it is unknown whyIBO prevalence rates differ between
populations, researchers hypothesized that this was due to environmental factors. The diet
of children of Burkina Faso is thought to resemble that of early agrarian societies, and is
composed of cereals, such as millet and sorghum, legumes, vegetables, and a small
amount of animal protein from chicken and termites. These children had gut microbiomes
rich in Prevote/la, Xyanibacter,

Butyrivibrio, and Treponema (bacterial genera are known

to produce short-chain fatty acids, which are thought to protect against intestinal
inflammation).In contrast, children in Italy ate diets high in animal proteins, sugars, and
fats, and low in fiber (De Filippo et al., 20I 0). This diet is common amongst Western
societies and has been associated with an increased risk ofIBO (Albenberg and Wu,
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2014; Celiberto et al., 2018). The intestinal microbiome of Italian children showed almost
no Prevotel/a bacteria and higher amounts of Bacteroides when compared to children of
Burkina Faso. In addition, the Italian children had significantly higher percentages of

Enterobacteriaceae, including Shigella and E. coli (bacterial pathogens known to cause
diarrhea), which were mostly absent in the intestines of children from Burkina Faso (De
Filippo et al., 20 I 0). A similar inverse relationship between Prevote/la and Bacteroides
has been seen in studies comparing the intestinal micro flora of individuals from South
America and Bangladesh to those from more industrialized nations (Albenberg and Wu,
2014).
Aside from comparing the intestinal microbiota of agrarian societies to that of
industrialized nations, research has also been conducted on the intestinal microbial
makeup of hunter-gatherer societies. One study on the Hadza hunter-gatherers of
Tanzania found significant differences in the intestinal microbiome of these populations
when compared to Italian populations. Similar to the population studied in Burkina Faso,
the majority (about 70%) of the energy needs of the Hadza came from plant food. As a
result, the gut microbiome of the hunter-gatherers in Tanzania consisted of features that
were consistent with a heavily plant-based diet. Like the Burkina Faso populations, the
intestinal microbiome of the Hadza included a higher percentage of Prevotella and a
lower abundance Bacteroides when compared to the Italian population. In addition,
Hadza populations exhibited increased biodiversity of the intestinal microbiome
compared to the Italian populations (Schnorr et al., 2014). A decrease in biodiversity due
to the loss of ancestral microbial species has been hypothesized to be linked to an
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increase in allergic and metabolic diseases (Blaser and Falkow, 2009). Therefore, a
decrease in diversity may also be linked to autoimmune disease such as IBD.
Interestingly, the intestinal microbiome of Hadza hunter-gatherers undergoes
cyclical changes in response to seasonal variation in dietary habits. During the wet season
(November through April), berry foraging and honey consumption is more successful.
However, during the dry season (May through October), the Hadza engage more
frequently in hunting strategies for subsistence. During these seasonal cycles, the
abundance of many taxa falls below the detectable range only to reappear in the next
season. These taxa that disappear in the Hadza at certain points of the year are also taxa
that are rare or absent in industrialized populations, such as those microorganisms
belonging to the Spirochaetaceae and the Succinivibrionaceae family (Smits et al., 2017).
The gut microbiota of wild black howler monkeys has also been observed to undergo
seasonal variation in bacterial taxa. It is hypothesized that this ability of the microbiome
to shift in response to dietary variation may have an adaptive function, as changes in
microbial taxa may help the host meet nutritional demands during times of resource
limitation resulting from seasonal variation (Amato et al., 20 l Sa).
In addition to cross-cultural studies on human diet and the intestinal microbiome,
studies on the biological implications of the changes in gut microbiota are essential to
understanding the relationship between these changes and IBO. It has been suggested that
human intestinal bacteria have coevolved with changes in diet (Ley et al., 2008). In both
the Burkina Faso and Hadza populations, it is hypothesized that the microbiota coevolved
with diet in order to maximize energy intake from indigestible carbohydrate compounds
(De Filippo et al., 201O; Schnorr et al., 2014). This evolution in gut microflora took the
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form of increased amounts of Pre vote/la, Xyanibacter, and Treponema. Coincidently,
these tax.a are mostly absent from the European children studied. In addition to fulfilling
the need to maximize energy intake from plant foods high in indigestible fiber, these
bacteria also produce short-chain fatty acids, which have been shown to protect against
intestinal inflammation. The high number Bacteroides observed in the European children
also help to produce short-chain fatty acids, suggesting an evolutionary need for their
production. However, the production level of these short-chain fatty acids was still less
than in the children of Burkina Faso (De Filippo et al., 2010).
Based on the above studies, it is likely that dietary changes that occur with
industrialization are a leading factor in the increased risk of IBD. The relationship
between these changes and IBD risk is most easily seen in Asia, where IBD was rarely
observed up until the last few decades (Lakatos, 2006). In Japan in particular, the number
of patients with IBD has increased l 00-fold within the last 30 years. Since World War II,
Japan has faced enormous cultural changes, including a shift to a more Westernized diet.
Prior to WWII, a typical Japanese diet consisted of mostly vegetarian meals comprised of
rice and barley, miso soup with root vegetables and/or tofu, fermented pickles, and a
small amount of animal protein from fermented fish. However, within the last few
decades, the Japanese diet has begun to include more foods associated with Western
diets. This includes higher amounts of sugars, fats, and animal proteins and a decrease in
the amount of dietary fiber (Kanai et al., 2014). It is likely that these dietary changes are
among the many factors that led to the 100-fold increase in IBD patients in Japan in the
last 30 years, and are likely impacting the worldwide incidence and prevalence rates as
well.
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Breastfeedi11g
Aside from cultural shifts in adult diets, changes in infant feeding practices may
also lead to an increased risk of IBD. The first studies on the link between breastfeeding
and IBD began in the 1960s when researchers discovered that patients with UC were
more likely to never have been breastfed (Mikhailov and Furner, 2009). Since then,
numerous studies have been conducted in order to find a link between breastfeeding and
the risk of IBO. However, many of these studies are either conducted with small sample
sizes or they fail to find any correlation between infant feeding practices and IBD risk
(Klement et al., 2004). Nonetheless, breastmilk has been associated with several health
benefits, such as protection against infectious diseases, asthma, allergies, and type 1
diabetes mellitus (Klement et al., 2004; Rinne et al., 2005), and may still play an
important role in the etiology of IBD.
Of these various health benefits, breastfeeding may reduce the risk of IBO by
selectively promoting the growth of intestinal bacteria that protect against pathogens and
immune-related diseases (Klement et al., 2004). Human milk oligosaccharides (MOS),
the third largest component of human milk, are indigestible by the human digestive tract
and remain intact as they travel through the colon. However, MOS are important
prebiotics that nourish the growth of certain intestinal bacterial species, specifically

Bifidobacteria. Bifidobacteria are thought to strengthen the intestinal mucosa! barrier by
increasing the production of immunoglobulin A (an antibody that plays a role in the
immune function of mucosal membranes) (Albenberg and Wu, 2014). Immunoglobulin A
is believed to enable secretion of antibodies on mucosa! surfaces, which protect against
dietary antigens and toxins and prevent the adhesion of potentially pathogenic bacteria to
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the intestinal epithelia (He et al., 2007). In addition, breastfed infants show greater
diversity in the Bifidobacteria populations than that of formula-fed infants, and exhibited
greater microbial diversity increases with weaning than formula-fed infants. In addition,

Bifidobacteria and Bacteroides are thought to have an inverse relationship with one
another (Albenberg and Wu, 2014). Since IBO is associated with decreased biodiversity
of the intestinal microbiota and increased amounts of Bacteroides (Kostic et al., 2014),
and changes in infant feeding practices may play an important role in altering the gut
microbial environment, it follows that IBO risk may be related to breastfeeding practices.
In the United States, these cultural changes to infant feeding practices may be able
to at least partially explain the trends in IBD incidence and prevalence rates.
Epidemiological studies suggest that the incidence rates of IBD have been increasing in
the United States since the early 1950s (Lakatos, 2006). At about the same time,
breastfeeding in the United States began to decline, and cow's milk and other early foods
began to replace breastmilk at a younger age. Although breastfeeding began increasing
again in the 1970s, this was also accompanied by an increase in fonnula fed infants after
4 months of age. By 1980, there was a 3 0% increase in the number of 6-month-old
formula-fed infants, and this percentage continued to increase through the 1990s (Fomon,
2001). Though it is possible that the relationship between these trends are coincidental, a
meta-analysis of breastfeeding and the risk of IBD supported the hypothesis that
breastfeeding was associated with a reduced risk of both UC and CD (Klement et al.,
2004). In addition, a study conducted on over 400 IBD patients and over 900 control
individuals from eight countries in Asia and in Australia found a strong protective
relationship between breastfeeding and reduced IBD development when infants were
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breastfed for 12 months or longer. This was hypothesized to be due to the effects of
breastfeeding on the development of the intestinal microbiome (Ng et al., 201 5).
Based on the above evidence, it is highly likely that a decrease in breastfeeding is
somehow linked to the in the increase of IBO risk. However, many of the studies that
have been conducted on the correlation between breastfeeding and IBO fail to define the
duration and exclusivity of breastfeeding practices (Klement et al., 2004). Since studies
have suggested that the length of breastfeeding is important to disease prevention (Ng et
al., 2015), future research on the link between breastfeeding and IBO should better define
both the duration and exclusivity of breastfeeding.

Appendectomy
Although it was once considered a vestigial organ, the appendix is now being
studied as an organ of evolutionary and medical importance. In IBO, appendectomies
have been linked to changes in the risk of disease development. Interestingly, undergoing
an appendectomy before 20 years of age leads to an increased risk of CD, but a decrease
in the risk of UC (Loftus, 2004). The reason for this difference in risk is not understood
(Scaldaferri et al., 20 13). Nevertheless, many Asian countries cite increasing incidence
rates of appendicitis and appendectomies as a risk factor for IBO (Ng et al., 201 5).
Unfortunately, cultural analysis of appendicitis and appendectomy rates are sparse, thus
the relationship between appendectomy and IBO will be examined here from a mostly
biological perspective.
A recent meta-analysis by (Ferris et al., 2017) has shown that although the rates of
appendicitis and appendectomies have stabilized or started to decrease in Western
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countries, these rates are increasing rapidly in newly industrialized countries. Thus, there
seems to be a correlation between industrialization, appendicitis, and IBO. Although
untangling the correlative from the causative factors may be difficult, examining the role
the appendix plays in intestinal health from an evolutionary perspective may be able to
elucidate the effects of industrialization on the appendix and consequent risk of 18D.
It is now thought that the appendix helps to modulate intestinal immune health
and is therefore no longer considered a vestigial organ. It has been hypothesized that the
location of the appendix in the lower bowel and its narrow shape allow it to exclude
pathogenic microorganisms and harbor commensal gut microbes (Bollinger et al., 2007).
In healthy individuals, the gut microbes of the appendix form microbial communities
known as biofilms, which are periodically shed into the large intestine. These biofilms
have been shown to regulate epithelial regeneration and protect against potential
pathogens (Scaldaferri et al., 2013).
In addition, the appendix is thought to play an important role in immune function
due to its association with a large amount of lymphoid tissue. This lymphoid tissue has
been shown to introduce mucin (a glycoprotein that protects intestinal surfaces) and IgA
(a molecule that identifies pathogens in mucosa) membranes) into the intestinal lumen
(the inside, hollow space of the intestine). Furthermore, both of these molecules have
been shown to regulate biofilm development in vitro and in vivo. Given that fecal
samples of patients with IBD have increased levels of lgA and biofilm formation, it is
possible that the appendix plays a role in the immune response in IBO (Bollinger et al.,
2007).
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There are two hypotheses for why removal of this beneficial organ may result in a
protective effect against UC. The first is that appendectomy removes specific intestinal
microbial species that cause inflammatory responses in patients with UC (Jackson et al.,
2014). The second hypothesis suggests that there might be a distinct microbial
composition of the appendix that predisposes individuals to appendicitis but protects
against UC. However, the exact bacterial mechanisms behind this remain unknown
(Ananthakrishnan, 2015; Jackson et al., 2014). Nevertheless, these hypotheses might also
help to explain why risk of CD may increase after an appendectomy. Still, research on the
effects of appendectomy on intestinal health are relatively scarce, and there is conflicting
evidence pertaining to the benefits of appendectomy for patients with UC (Parian et al.,
2017). Future research should be conducted in order to clarify the exact role that the
appendix plays in shaping the intestinal microbiome and in modulating intestinal immune
health.

A11tibiotics
The discovery of penicillin in 1928 led to a medical revolution that saved the lives
of many from life-threatening infections (Neuman et al., 2018). Nonetheless, childhood
antibiotic exposure has been identified as a risk factor for IBD and is associated with
dysbiosis of the gastrointestinal microbiome (Francino, 20 I 6; Kaplan, 2015; Lewis et al.,
2015). Broad-spectrum antibiotics affect the abundances of 39% of the bacteria in the
gut, and antibiotic-induced changes can remain for months to years after initial treatment.
Although the microbiome may eventually return to a composition similar to that of the
composition before antibiotic treatment, the original composition is never fully recovered
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(Francino, 2016). Antibiotics may even be used to treat IBO (Salaga et al., 2014); thus, it
is important to understand how antibiotics affect the gut microbiota.
Antibiotics are the most prescribed medication in neonatal and pediatric
populations in the US (Gibson et al., 2015; Neuman et al., 2018). When given before
birth, antibiotics have been shown to alter the mother's microbiome, and can cross the
placenta and enter the fetus, which may affect the initial inoculation of the infant.
Prenatal maternal antibiotics are prescribed for urinary tract infection, sinus infections,
ear infections, and other bacterial infections. In addition, peripartum antibiotics are often
given for prolonged rupture of membranes, Group B streptococcus colonization, C
section, or chorioamnionitis, and postpartum antibiotics may be prescribed for
endometritis, surgical site infections, and mastitis. Additionally, pre-, peri-, and postnatal
antibiotic usage is extensive among breastfeeding mothers (Lemas et al., 2016).
Subtherapeutic antibiotic exposure in infancy, such as through breastmilk, may also
affect the developing microbiome. Mice exposed to subtherapeutic antibiotics in drinking
water had a significant decrease in the ratio of Bacteroides to Firrnicutes, but no overall
change in the bacterial load (Gibson et al., 2015). Furthermore, human infants whose
mothers received antibiotics during labor and delivery to prevent infection had
microbiomes that were significantly different than that of infants whose mothers did not
receive treatment (Arboleya et al., 2015). Additionally, low birthweight newborns whose
mothers had been given antibiotics to prevent Group B streptococcus infection had an
increase in Escherichia coli (Ledger and Blaser, 2013), and preterm infants treated with
antibiotics and infants whose mothers received antibiotics had low abundance of

Bifidobacterium and low bacterial diversity, which correlated with the onset of
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necrotizing enterocolitis (Francino, 201 6). Necrotizing enterocolitis is an inflammatory
disease that primarily affects the bowels of preterm infants (although similar symptoms
can appear in term and late-term infants), and has an estimated rate of death between
twenty and thirty percent (Neu and Walker, 201 1 ). Therefore, understanding how
antibiotics affect the intestinal microbiome may shed light on how they may lead to the
development of inflammatory bowel disorders.
A longitudinal study of 39 children during their first three years of life compared
the microbial diversity of antibiotic treated and untreated children. Those children who
were treated with antibiotics had decreased microbial diversity and increased short-tenn
composition changes of their gut microbiota. In addition, antibiotic treated children had
less stable gut microbiomes than untreated children (Yassour et al., 201 6). A study on
1 42 Finnish children aged two to seven found that antibiotics disrupt microbial
composition and metabolism. Compared to untreated children, children who received
antibiotics had an increase in members of the Bacteroidetes and Proteobacteria phyla
(including Enterobacteriaceae) and a decrease in members of the Actinobacteria phyla,
including Bifidobacteria (Korpela et al., 201 6).
Antibiotic exposure in childhood may also alter immune response, causing
abnormal inflammatory responses that can create dysbiosis of the gut microbiome (Lewis
et al., 201 5). Antibiotics have been observed to alter the stimulation of NOD 1 and Toll
like receptors (molecules that sense microorganisms in the early innate immune
response), which can affect lymphoid (immune system) tissue development, T-cell (white
blood cell) differentiation, neutrophil (innate immune system white blood cells) priming,
production of antibacterial compounds, and cytokine (cell-signaling molecules) release
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(Francino, 201 6). In mice, early exposure to antibiotics triggered a stress response that
increased corticosterone levels and led to an enhanced function of CD4• T cells, which
ultimately caused a rapid onset of IBO (Scheer et al., 2017).
Although antibiotics have saved countless lives, the use of these medications is
not without consequences, as they have been found to cause disruption of the microbiota
and the immune response. Although the adult microbiome is thought to be able to recover
from a single antibiotic exposure within two weeks, multiple treatments can impair
recovery. As with any ecosystem, repeated perturbations of the microbiome are
especially harmful if it is not given time to recover (Yassour et al., 201 6). Therefore,

repeated antibiotic exposure in infancy and childhood could cause irreparable damage to
a developing gut ecosystem. This, combined with an altered immune response, is thought
to increase IBO risk.

E11viro11mental Radiation
Following the atomic bombings of Nagasaki and Hiroshima, there was a
significant increase in the number of individuals with digestive diseases (Preston et al.,
2012). In areas where nuclear accidents have occurred, such as the Chernobyl Exclusion
Zone in Ukraine, animals like bank voles (Myodes glareo/us) have been observed to have
altered microbiorne compositions and functions (Lavrinienko et al., 2018). However,
continuous low-dose radiation not resulting from nuclear accidents or events may also
impact host-microbial interactions. Low-LET (linear energy transfer) radiation, from X
or y-irradiation, indirectly affects cells by producing reactive oxygen species (ROS) that
can cause DNA and protein damage and can trigger stress responses in microbial and host
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cells (Zhang and Steen, 2018). Therefore, radiation exposure may lead to altered immune
responses and dysbiosis of the microbiome that could result in IBO.
Radiation enteropathy, which can arise in patients receiving abdominal or pelvic
radiotherapy for cancer, includes symptoms such as malabsorption, bloating, diarrhea,
dehydration, abdominal pain, anorexia, nausea, and vomiting (Packey and Ciorba, 20 I 0).
Many of these symptoms are similar to those observed in IBO patients. Furthermore, in
both IBO and radiation enteropathy, the expression of cytokines (cell-signaling
molecules) including interleukin I p (IL-I P), TN Fa, and TGF� is increased, and the
microbiome is altered (Ferreira et al., 2014). In mice, localized dysbiosis caused by
radiation therapy promotes mucosa! IL- Ip secretion, which can contribute to radiation
induced tissue damage and inflammation and renders germ-free mice more susceptible to
OSS-induced colitis and radiation damage (Gerassy-Vainberg et al., 201 8). In addition,
patients with IBO are more likely to develop radiation enteropathy, and the microbial
profiles of individuals prior to radiation therapy may determine if the patient develops
radiation enteropathy (Packey and Ciorba, 20 I 0).
It is unclear as to whether a dysregulated inflammatory response causes
gastrointestinal dysbiosis or if dysbiosis initiates an inflammatory response leading to
180. Research on radiation enteropathy, which has symptoms similar to IBO, has
suggested that the dysbiosis precedes the inflammatory response (Gerassy-Vainberg et
al., 20 1 8). However, other investigators have suggested that increased TN Fa levels
resulting from radiation exposure can increase intestinal permeability and apoptosis and
make the epithelium more susceptible to pathogenic bacteria (Ferreira et al., 2014). It is
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possible that a combination of dysbiosis caused by external factors and an altered
immune response are responsible for IBD onset.
Due to the nature of the disease, patients with IBD are exposed to higher amounts
of radiation from diagnostic imaging, such as CT scans, than patients with other
gastrointestinal disorders (Desmond et al., 201 2). Not only does this increase the risk of
malignancy in this population (Desmond et al., 201 2; Newnham et al., 2007), but given
that continuous radiation exposure can lead to disruption of the immune response and
microbial ecosystem of the gut (Zhang and Steen, 2018), repeated radiation exposure
from diagnostic imaging may worsen symptoms in IBD patients. It is thus important to
reduce the amount of radiation exposure from diagnostic imaging in IBD patients.

Treatments for IBD
Although there is no cure for IBD, there are a number of treatments available.
Current treatments primarily target abnormal host immune responses (Celiberto et al.,
20 1 8). In Western societies, IBD patients are most concerned with the course of the
disease, possibility of ostomy surgery, medication side-effects, and disease complications
(Levenstein et al., 2001 ). As IBD becomes a global disease, it will be increasingly
important to develop treatments that efficiently combat symptoms with the fewest side
effects.
Current treatments for IBO include corticosteroids, immunosuppressive drugs
(such as 5-arninosalicyclic acid), immunomodulators (such as azathioprine and
methotrexate), and biologics (Celiberto et al., 201 8; Mulder et al., 201 4; Salaga et al.,
2014). Biologics are antibodies that inhibit inflammation through targeting pro-
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inflammatory cytokines tumor necrosis factor-a (TNF-a) or interleukin-12 (IL12)/23p40, or preventing immune cell recruitment in the gut (Celiberto et al., 2018).
Biologics are often used when other treatments fail (Wentworth et al., 2018) and have
become of great interest to researchers developing IBD treatments (Mulder et al., 20 t 4).
However, biologics and steroids can lead to increased risk of infection or cancer
(Celiberto et al., 20 t 8). Therefore, there is a need for better treatment options for IBD.

Alterations to tlte Microbiome (Probiotics and Fecal Microbiota Transplants)
Although the most common treatments for IBD target pathological immune
responses, therapies that treat dysbiosis of the gut microbiome have also been considered.
These therapies include probiotics and fecal microbiota transplants (FMT). In both
probiotic therapy and FMT, live microorganisms are used to improve patient health
outcomes through temporary alteration of the gut microbiome (Celiberto et al., 2018;
Goyal et al., 20 t 8).
Probiotics have been suggested as a possible therapy for IBD due to their ability
to provide host organisms with certain health benefits. The Food and Agriculture
Organization/World Health Organization (FAO/WHO) describes probiotics as "live
microorganisms which when administered in adequate amounts confer a health benefit on
the host" (Jensen et al., 2012). Lactobacillus casei Shirota was found to restore normal
stimulatory capacity of dendritic (antigen-presenting immune) cells in patients with UC
by reducing the expression of toll-like receptors (proteins expressed on immune cells that
recognize microbial compounds and initiate immune response) TLR2 and TLR4. In mice,
a combination of eight different probiotic strains have been shown to reduce disease
activity and inflammation with dextral sulphate sodium (DSS) colitis (experimentally-
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induced colitis in animal models). Furthermore, L. p/antarum 299V and L. plantarwn
VSL#3 have been shown to prevent colitis development and improve colitis and disease
activity in IL-I 0-deficient mice (Celiberto et al., 2018). However, in humans, probiotics
have no benefit when compared to placebo in inducing remission of active UC,
preventing relapse of UC or CD, or preventing clinical or endoscopic relapse of post
operative CD (Derwa et al., 2017). The lack of clinical success may be attributed to an
inefficient one-size-fits-all approach, the inability of new organisms to take up a
permanent residence in the gut, and an inflamed intestinal environment that is
inhospitable for many probiotic organisms (Celiberto et al., 2018).
Fecal microbiota transplants have also been posited as potential therapies for
restoring the gastrointestinal microbiome ofIBO patients to a healthy state. Fecal
microbiota transplants involve the transplant of fecal or stool matter from a healthy donor
to a patient's GI tract to restore healthy conditions, and was labeled by the FDA as an
lnvestigational New Drug forIBO in 2016. Aside from restoring microbial organisms to
the gastrointestinal tract, FMT improves immune function by regulating inflammatory
markers through the inhibition of T cell, leukocyte adhesion, and the production of
inflammatory markers. In addition, FMT helps to reduce permeability of the epithelial
barrier by increasing the number short-chain fatty acid producing microorganisms
(Sunkara et al., 2018). A study assessing the safety, clinical response, and changes in the
gut microbiome to FMT in children with UC, CD, and indeterminate colitis found that
57% of patients demonstrated clinical response at one month, 28% demonstrated clinical
response at six months, and two patients with CD were at remission at six months post
transplant. Although patients had an increase in intestinal species diversity at one month,
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most of these changes shifted back toward the baseline by six months. Therefore, FMT
can create short-term changes in patients with active IBD; however, more research must
be conducted to determine if any of these effects can be long-lasting (Goyal et al., 2018).

Complementary a11dAltemative Medici11e
Complementary and alternative medicine (CAM) products include herbal
medicine, dietary supplementation, and mind-body medicine, such as acupuncture,
moxibustion (a traditional Eastern medicine therapy that involves burning dried moxa, a
plant related to mugwort, on or near a person's skin), and hypnotherapy. It is estimated
that the prevalence of current and past use of CAM in North America and Europe ranges
from 21-60%. Those patients with IBD who are of younger age, female, have achieved a
higher education level, and have experienced adverse drug reactions from IBD treatments
(such as extra-intestinal manifestations of18D and psychological stress as the result of
their medications and/or prolonged, intense steroid use) are more likely to use CAM.
Furthermore, a study in Germany found that 48% of IBD patients believed that a
scientific foundation of CAM was important and 65% of IBD patients reported that they
would continue to use CAM even if scientific reports showed it to be ineffective (Ng et
al., 2013). Given the popularity of CAM, both in Eastern and Western societies, it is
important to understand their efficacy in treating IBD.
A number of herbal therapies have been observed to be superior to the placebo in
treating IBD symptoms. One of these herbal therapies is Aloe Vera gel, which is believed
to have anti-oxidant, anti-inflammatory, anti-ageing, anti-cancer, immune boosting, and
other healing properties and has been used by Egyptian, Chinese, Indian, and European
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cultures for over 5000 years to treat skin and digestive diseases (Langmead et al., 2004).
In addition, treatment with wheatgrass juice (Triticum aestivum), which was popularized
in the United States by Dr. Ann Wigmore more than 40 years ago as a therapy for chronic
inflammatory disorders and other illness, has been shown to reduce disease activity in
patients with active UC (Ben-Arye et al., 2002). The traditional Chinese medicines

Andrographis paniculata extract (HMPL-004) (traditionally used to treat infections),
Xilei-san (traditionally used to treat ulcerations of the pharynx, tongue, and mouth), and

Tripterygium wilfordii (used to treat autoimmune and inflammatory disorders) have also
demonstrated therapeutic properties (Ren et al., 2013; Salaga et al., 2014; Zhang et al.,
2013). Furthermore, wormwood (Artemisia absinthium), a traditional medicine used for
centuries in Europe to treat a wide variety of ailments, performs better than placebo in
treatment of CD symptoms and has been shown to improve the mood of patients with CD
(Krebs et al., 2010) (Table I).
Some herbal therapies have been shown to be as effective as common allopathic
treatments for IBO. In particular, Boswellia serrata gum resin and Plantago ovata have
been observed to be as effective as mesalazine (a common allopathic medicine) in
treatment of UC (Ng et al., 2013). The medicinal properties of Boswellia serrata resin
(commonly known as frankincense) were first described by the Egyptians in the Ebers
papyrus around 1500 BCE, and it is now used for a variety of medicinal purposes around
the world. In Kenya, Boswellia serrata resin is used to treat wounds and prevent blood
loss from schistosomiasis infection. It is used in China to treat skin infections and bruises
and in Ethiopia as a tranquilizer. In India, Boswellia resin is used to treat a number of
inflammatory disorders, including Crohn's disease (Moussaieff and Mechoulam, 2009).
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Plantago ovata seeds are used in traditional medicine in Asia as a source of fiber to
improve intestinal functions (Goncalves and Romano, 2016) (Table 1 ).

Table 1 : Herba I th erap1es tiound to improve IBO symptoms.
Herbal Therapies

Country/Continen
t
where it is used

Aloe Vera Gel

Egypt, China, India,
Europe

Wheatgrass Juice
(Triticum aestivum)

United States

Andrographis
panicu/ata extract
(HMPL-004)
Xilei-san

China

Tripterygium
wilfordii
Wormwood
(Artemisia
absinthium)
Frankincense
(Boswel/ia serrata
resin)

China

Plantago ovata
seeds

China

Europe
Kenya, Ethiopia,
China, India

Asia

Traditional Uses

Performs Better
Than

Anti-oxidant, antiinflammatory, antiageing, anti-cancer,
immune boosting
Treatment of
chronic
inflammatory
diseases
Treatment of
infection

Placebo

Treatment of
ulcerations on
tongue, mouth, and
pharynx
Treatment of
immune disorders
Treatment of a
variety of ailments

Placebo

Treatment of
wounds, blood loss,
skin infections,
bruises, and
inflammatory
disorders. May be
used as a
tranquilizer
<Ethiooia)
Improve intestinal
function

Placebo

Placebo

Placebo
Placebo
Mesalazine

Mesalazine

Dietary supplementation is also common among IBO patients. Dietary
supplementation includes probiotics, prebiotics, and fish oil (Ng et al., 2013). Prebiotics
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are substances that are selectively used by host microorganisms and confer a health
benefit to the host. Prebiotics include inulin-type fructans, galacto-oligosaccharides,
lactulose, p-glucans, arabinoxylan oligosaccharides, xylo-oligosaccharides, soy bean
oligosaccharides, isomalto-oligosaccharides, and pectin, most of which are sugars that
come from plants. However, prebiotics have not been shown to consistently improve or
worsen IBO symptoms (Celiberto et al., 201 8). Omega-6 (n-6) and omega-3 (n-3)
polyunsaturated fatty acids (PUFA) found in fish oil are thought to mediate immune and
inflammatory responses, and increased intake is thought to reduce inflammation and
reduce the risk of IBO (Wall et al., 201 0).

Discussion
The ability of the gastrointestinal microbiome to undergo rapid changes in
response to environmental changes has been hypothesized to help the host meet
physiological demands (Amato et al., 20 I Sa). In fact, the composition of the micro biota
may be shaped more by the environment than by the host's genetics. Adult monozygotic
twins have microbiomes that are no more similar in composition than adult dizygotic
twins. In addition, genetically unrelated cohabitating spouses have microbiomes that are
significantly more similar to one another than members of different households
(Yatsunenko et al., 20 12). Furthermore, dogs (Canis lupusfamiliaris) have microbiomes
that are more similar to humans than the microbiomes of pigs or mice, and they exhibit a
similar response to dietary changes. The observed similarity between the dog and human
microbiomes is most likely due to shared environments and lifestyles (Coelho et al.,
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201 8). Therefore, as humans alter the visible environment, microbial ecosystems (like
those within the gut) are also likely affected.
One result of industrialization is better access to healthcare and improved
diagnostic technology. This has been associated with increased incidence and prevalence
rates of IBD (Kaplan, 2015). Although this may be associated with an increase in the
number of patients diagnosed with IBD, it cannot explain the initial cause of the disease.
Since IBO has been linked to a relationship between environmental factors, the intestinal
microbiome, and host biology (Kostic et al., 2014; Loftus, 2004), the relationship
between these factors should be elucidated.
According to the hygiene hypothesis, industrialization may have led to the loss of
key regulatory members, including helminths. Once ubiquitous in human gastrointestinal
tracts, these worm-like parasites have evolved mechanisms for down-regulating intestinal
immune responses. In the absence of helminths, these immune responses are able to
operate at full capacity, ultimately resulting in immune dysfunction. It has been suggested
that reintroducing these members or their regulatory molecules to the gastrointestinal
tract may help to reduce the risk of developing IBD (Weinstock and Elliott, 2009).
One environmental factor that is often linked to IBD risk is diet. From an
evolutionary standpoint, taxonomic shifts in the composition of the microbiome may
have improved energy production and fat storage in early humans. However, these
changes may have also made humans more susceptible to obesity and metabolic and
immune disorders in times when food is abundant (Amato et al., 2015b; Celiberto et al.,
2018). Further, diets high in indigestible fiber support the growth of bacteria known to
produce short-chain fatty acids, which help protect against intestinal inflammation (De
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Filippo et al., 20 l 0). Since urbanization leads to diets high in sugar, animal fats and
proteins, and processed foods (Drewnowski and Popkin, 1997), it is likely that dietary
shifts are causing changes in the microbiome that increase the risk of obesity, metabolic
disorders, and inflammatory diseases.
Breastfeeding has also been associated with IBD risk. However, there have been
contradictory results about the relationship between breastfeeding and IBD (Ng et al.,
2015). Nevertheless, breastfeeding is thought to protect against IBD by promoting the
growth of beneficial bacteria that prevents intestinal inflammation and the adhesion of
pathogens to the gut epithelium (Klement et al., 2004). Breastmilk contains human milk
oligosaccharides that promote the growth of Bifidobacteria, which produce
Immunoglobulin A (Albenberg and Wu, 2014), an antibody that helps protect against
pathogens (He et al., 2007). Therefore, the usage of formula that does not contain human
milk oligosaccharides may affect the growth of Bifidobacteria in the gut. This may affect
the production of certain immune molecules in the gut, such as Immunoglobulin A, and
increase the risk of chronic immune disorders, such as IBD.
Like breastfeeding, there is conflicting evidence for whether or not appendectomy
prevents the development ofIBD. Although it may protect against UC, it is associated
with an increased risk of CD. The reasons for this are not well known (Loftus, 2004), but
it may be associated with the evolutionary role of the appendix. Despite once being
considered a vestigial organ, the appendix is now thought to have a number of functions,
including the production of immunomodulatory molecules and protection of beneficial
organisms (Bollinger et al., 2007). Appendectomy may therefore result in changes in both
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immune function and the gut microbiome, possibly leading to a chronic inflammatory
response.
High antibiotic exposure in childhood has been associated with dysbiosis of the
microbiome and increased risk ofIBD (Francino, 201 6; Kaplan, 201 5 ; Lewis et al.,
201 5). Antibiotics have also been shown to negatively impact immune function (Scheer
et al., 201 7). Even if the microbiome is thought to be able to largely recover two weeks
after antibiotic exposure (Yassour et al., 201 6), some changes may continue to last for
years (Francino, 201 6). Repeated exposure to antibiotics may prevent full recovery of the
gut ecosystem. Dysbiosis combined with an impaired immune response as a result of
excessive antibiotic use may increase IBD risk.
Low-dose radiation exposure may also increase risk of IBD or worsen symptoms
in patients with 18D. Like antibiotics, radiation exposure can lead to dysbiosis of the gut
microbiome (Gerassy-Vainberg et al., 201 8}. Radiation exposure can lead to genetic and
protein damage in host and bacterial cells (Zhang and Steen, 2018) and has been shown
to disrupt the immune response (Ferreira et al., 2014). Disruption of both the intestinal
ecology and host biology due to radiation exposure may worsen inflammatory responses
and lead to chronic illness.
As with any environmental stressor, humans have begun attempting to reduce the
negative symptoms that occur with IBD. For the most part, behavioral adaptations in
terms of medicinal treatments are used to alleviate IBD symptoms. Many of these
treatments affect the composition of the gut microbiome and/or the immune response.
Given that a number of environmental factors have been associated with disease

37

development, it may be helpful to pursue treatment options that reduce the impact of
these factors.
Like all organisms, humans adapt and acclimatize to changing environments. It is
possible that repeated perturbations to the gastrointestinal ecosystem caused by external
factors associated with industrialization may create a change in the environment to which
the body must adapt. The chronic inflammatory response observed in IBD is likely
induced both by external factors outside of the gut and internal factors within the gut.
Inflammation can cause further dysbiosis of the gut microbiome, which can in tum lead
to a greater inflammatory response (Celiberto et al., 2018), eventually resulting in chronic
inflammation of the gastrointestinal tract. Nevertheless, some of these factors (antibiotics,
radiation exposure) have also been shown to impact the immune response. Furthermore,
there is a discrepancy as to whether dysbiosis precedes a disrupted immune response or if
a disrupted immune response precedes dysbiosis (Gerassy-Vainberg et al., 2018). In this
case, it may be helpful to examine IBD through an evolutionary systems theory in which
a change in one factor affects all other factors. Future studies should examine the ways in
which the environment, intestinal rnicrobiome, and host biology interact.
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